Valence Therapeutics Inc Evanston, IL - 60201

Valence Therapeutics Inc is categorized under Research and Development Laboratories in Evanston, IL and active since 2009.

Valence Therapeutics Inc was established in 2009, and today employs 1 to 4, earning $50.000 to $99.999 per year. This is a Research and Development Laboratories business, which does work in the B2B market, and is classified as a Research and Development Laboratories, under code number 541712 by the NAICS.

If you are seeking more information, feel free to contact Andrew P Mazar at the company’s single location by writing to 1007 Church St # 307, Evanston, Illinois IL 60201 or by phoning (847) 869-0785. You can also visit this business on Facebook by going to their profile page at Facebook or on find them on Twitter.

Business Name: Valence Therapeutics Inc
Contact Person: Andrew P Mazar
Address: 1007 Church St # 307, Evanston, Illinois 60201
Phone Number: (847) 869-0785
Annual Revenue (USD): $50.000 to $99.999
Founded: 2009
Location Type: Single Location
Employee Number: 1 to 4
Business Type: B2B (Business to Business)
Business Category: Research and Development Laboratories
SIC Code: 8731
NAICS Code: 541712
Share This Business:

Valence Therapeutics Inc was started in 2009 to provide professional Research and Development Laboratories under the SIC code 8731 and NAICS code 541712. Since its inception, the company has gone on to take a total of 1 to 4 personnel under its employment and has achieved earnings of $50.000 to $99.999 per annum.

Feel free to contact Andrew P Mazar for inquiries that concern Valence Therapeutics Inc by calling the company number (847) 869-0785, as your correspondence is most welcome. Additionally, the physical location of the single location of Valence Therapeutics Inc can be found at the coordinates 42.048632,-87.686157 as well as the street address 1007 Church St # 307 in Evanston, Illinois 60201.

For its online presence, you may visit Valence Therapeutics Inc’s website at and engage with its social media outlets through on Twitter and on Facebook.